

## Publications on which at least one of our team members is involved

1. Bioequivalence study of two Ibuprofen formulations administered intravenously in healthy male volunteers **Chassard D, Geneteau A, Gualano V, Brault M**. *Clin. Drug. Invest.* 24(12): 739-747, 2004

<http://www.ncbi.nlm.nih.gov/pubmed/17523737>

2. Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency **Chatelut E, Rostaing L, Gualano V, Vissac T, De Forni M, Ton-That H, Suc JM, Houin G, Canal P**. *Nephron.* 66(2):157-61, 1994

<http://www.ncbi.nlm.nih.gov/pubmed/8139735>

3. Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers **de Forni M, Gualano V, Canal P, Martel P, Izar-Soum F, Chevreau C, Soulie P, Roche H, Bugat R**. *Bull Cancer* 80(5):408-17, 1993 (French)

<http://www.ncbi.nlm.nih.gov/pubmed/8173194>

4. Comparative bioavailability study of two omeprazole formulations after single and repeated administrations **Duvauchelle T, Millérioux L, Gualano V, Evène E, Alcaïde A**. *Clin. Drug Investigation*, 16, 141 -149, 1998

<http://www.ncbi.nlm.nih.gov/pubmed/18370532>

5. Population pharmacokinetics of ibuprofen enantiomers in very premature neonates **Grégoire N, Gualano V, Geneteau A, Millerioux L, Brault M, Mignot A, Roze J.C**. *J Clin Pharmacol.* 44: 1114-24, 2004

<http://www.ncbi.nlm.nih.gov/pubmed/15342612>

6. Safety and pharmacokinetics of paracetamol following intravenous administration of 5 g during the first 24 h with a 2-g starting dose **Gregoire N, Hovsepian L, Gualano V, Evène E, Dufour G, Gendron A**. *Clin. Pharm; Ther.*, 81(3):401-5, 2007

<http://www.ncbi.nlm.nih.gov/pubmed/17339870>

7. Comparative bioavailability of two oral nimodipine formulations after administration to 24 healthy volunteers **Gualano V, Ntssikoussalabongui B, Mignot A, Duvauchelle T, Felices M, Guillaume M, Orlandini B, Holguin J, Alcaïde A**. *Clin. Drug Investig.* 17; 6: 475-82, 1999

<http://www.ingentaconnect.com/content/adis/cdi/1999/00000017/00000006/art00008>

8. Multiple-dose pharmacokinetics and excretion balance of gatifloxacin, a new fluoroquinolone antibiotic, following oral administration to healthy Caucasian volunteers **Mignot A, Guillaume M, Brault M, Gualano V, Millerioux L, Gohler K, Stahlberg HJ**. *Chemotherapy*. 48(3):116-21, 2002

<http://www.ncbi.nlm.nih.gov/pubmed/12138326>

9. High-performance liquid chromatographic determination of baclofen in human plasma **Millerioux L, Brault M, Gualano V, Mignot A**. *J Chromatogr A*. 5;729(1-2):309-14, 1996

<http://www.ncbi.nlm.nih.gov/pubmed/9004955>

10. Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study **Montastruc JL, Rascol O, Senard JM, Gualano V, Bagheri H, Houin G, Lees A, Rascol A**. *Clin. Neuropharmacol.*, 14(5):432-7, 1991

<http://www.ncbi.nlm.nih.gov/pubmed/1742752>

11. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion **Muller C, Chatelut E, Gualano V, De Forni M, Huguet F, Attal M, Canal P, Laurent G**. *Cancer Chemother Pharmacol.*; 32(5): 379-84, 1993

<http://www.ncbi.nlm.nih.gov/pubmed/8339389>

12. Pharmacokinetics and tolerability of prulifloxacin after single oral administration **Piccolo R, Brion N, Gualano V, Millerioux L, Marchetti M, Rosignoli MT, Dionisio P**. *Arzneimittelforschung*; 53(3):201-5, 2003

<http://www.ncbi.nlm.nih.gov/pubmed/12705176>

13. Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men **Raynaud JP, Aumonier C, Gualano V, Betea D, Beckers A**. *J Steroid Biochem Mol Biol*, 109(1-2):177-84, 2008

<http://www.ncbi.nlm.nih.gov/pubmed/18325758>

14. Plasma levels of glyceryl trinitrate and dinitrates during application of three strengths of a new glyceryl trinitrate transdermal patch **Santoro A, Rovati LC, Follet M, Setnikar I, Caplain H, Gualano V**. *Arzneimittelforschung*;50(9):786-94, 2000

<http://www.ncbi.nlm.nih.gov/pubmed/11050694>

15. Bioavailability and pharmacokinetic profile of glyceryl trinitrate and of glyceryl dinitrates during application of a new glyceryl trinitrate transdermal patch **Santoro A, Rovati LC, Setnikar I, Caplain H, Gualano V**. *Arzneimittelforschung*, 50(9): 779-85, 2000

<http://www.ncbi.nlm.nih.gov/pubmed/11050693>

16. Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch **Setnikar I, Rovati LC, Santoro A, Guillaume M, Mignot A, Renoux A, Gualano V.** *Arzneimittelforschung*; 49(8): 708-15, 1999

<http://www.ncbi.nlm.nih.gov/pubmed/10483519>

17. Pharmacokinetics of estradiol and of estrone during application of three strengths of an estradiol transdermal patch with active matrix **Setnikar I, Rovati LC, Thebault JJ, Guillaume M, Mignot A, Renoux A, Gualano V.** *Arzneimittelforschung*, 47(7):859-65, 1997

<http://www.ncbi.nlm.nih.gov/pubmed/9272245>

18. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. **Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evène E, Guastalla JP, Négrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C.** *Cancer Chemother Pharmacol.* 1998

<http://www.ncbi.nlm.nih.gov/pubmed/9488597>

19. Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149. **Dirix L, Catimel G, Koier I, Provè A, Schrijvers D, Joossens E, De Bruijn E, Ardiet C, Evène E, Dumortier A, et al.** *Anticancer Drugs.* 1995

<http://www.ncbi.nlm.nih.gov/pubmed/7756684>

20. A single-center, open-label, cross-over study of pharmacokinetics comparing topical zinc/clindamycin gel (Zindaclin) and topical clindamycin lotion (Dalacin® T) in subjects with mild to moderate acne **Chassard D, Kanis R, Namour F, Evène E, Ntssikoussalabongui B, Schmitz V.,** *J Dermatolog Treat*, 17(3): 154-157, 2006

<http://www.ncbi.nlm.nih.gov/pubmed/16854755>

21. Bayesian estimation of pharmacokinetic parameters of etoposide **Evène E., Tranchand B., Chatelut E., Canal P., Ardiet C.** *Bulletin du Cancer*, 84, 699 – 703, 1997(French)

<http://www.ncbi.nlm.nih.gov/pubmed/9339195>

22. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. **Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M, Calvez V, Brun-Vézinet F.** *J Antimicrob Chemother*, 63(3):585-92, 2009

<http://www.ncbi.nlm.nih.gov/pubmed/19147519>

23. Bioequivalence study of two formulations (sachet and tablet) of cefixime after single oral doses of 200 mg in healthy male volunteers. **Evène E., Brault M., Manche M., Sibille M., Montay G., Vital Durand D.**, *Clin. Drug Investigation*, 21, 287 – 94, 2001

<http://www.ingentaconnect.com/content/adis/cdi/2001/00000021/00000004/art00007>

24. Pharmacokinetics of repaglinide in healthy Caucasian and Japanese Subjects **Thomsen M.S., Chassard D., Evène E., K.K. Nielsen, M. Jørgensen.**, *J Clin Pharmacol*, 43, 23-28, 2003

<http://www.ncbi.nlm.nih.gov/pubmed/12520624>

25. Phase I pharmacokinetic study of high dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas **Tranchand B., Lucas C., Biron P., Giroux B., Gordon B., Richards R., Solere P., Roux N., Evène E., Mornex F., Clavel M., Ardiet C.** *Cancer Chemother. Pharmacol.*, 32, 46 – 52, 1993

<http://www.ncbi.nlm.nih.gov/pubmed/8462123>

26. Statistical investigation of the full concentration range of fasted and fed simulated intestinal fluid on the equilibrium solubility of oral drugs **Jeremy Perrier, Zhou Zhou, Claire Dunn, Ibrahim Khadra, Clive G Wilson, Gavin Halbert** *European Journal of Pharmaceutical Sciences. Elsevier*, 111(June 2017), pp. 247–256

<https://www.ncbi.nlm.nih.gov/pubmed/28987539>

27. Dual level statistical investigation of equilibrium solubility in simulated fasted and fed intestinal fluid. **Bayan E Ainousah, Jeremy Perrier, Zhou Zhou, Claire Dunn, Ibrahim Khadra, Clive G Wilson, Gavin Halbert** *Mol. Pharmaceutics*, 2017, 14 (12), pp 4170-4180

<https://www.ncbi.nlm.nih.gov/pubmed/29072917>

28. The topography of simulated intestinal equilibrium solubility **Claire Dunn, Jeremy Perrier, Zhou Zhou, Ibrahim Khadra, Clive G Wilson, Gavin Halbert** *Mol. Pharm.* 2019 May 6;16(5):1890-1905

<https://www.ncbi.nlm.nih.gov/pubmed/30848917>

29. Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation **Christian Funck-Brentano, Antonella Bacchieri, Giovanni Valentini, Silvia Pace, Silva Tommasini, Pascal Voiriot, David Ubben, Stephan Duparc, Eric Evène, Mathieu Felices & Marco Corsi** *Scientific Reports* 9(1):883 · December 2019

<https://www.nature.com/articles/s41598-018-37112-6>

30. Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method **Christian Funck-Brentano, Nouhoum Ouologuem, Stephan Duparc, Mathieu Felices, Sodiomon B. Sirima, Issaka Sagara, Issiaka Soulama, Jean-Bosco Ouedraogo, Abdoul H. Beavogui, Isabelle Borghini-Fuhrer, Yasmin Khan, Abdoulaye A. Djimdé & Pascal Voiriot** *Sci Rep.* 2019 Jan 29;9(1):883

<https://www.ncbi.nlm.nih.gov/pubmed/30696921>

31. Can an early phase clinical pharmacology study replace a thorough QT study? Experience with a novel H3-receptor antagonist/inverse agonist **Rashmi R Shah, Pierre Maison-Blanche, Philippe Robert, Emmanuel Denis, Thierry Duvauchelle** *Eur J Clin Pharmacol.* 2016 May;72(5):533-43

<https://www.ncbi.nlm.nih.gov/pubmed/26879827>

32. A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years **Mario Scala, Meriam Koob, Sophie de Buttet, Philippe Bourrinet, Mathieu Felices and Elzbieta Jurkiewicz** *Invest Radiol.* 2018 Feb;53(2):70-79

<https://www.ncbi.nlm.nih.gov/pubmed/28906338>

33. Determination of an Optimal Dosing Regimen for Fexinidazole, a Novel Oral Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Studies **Antoine Tarral, Séverine Blesson, Olaf Valverde Mordt, Els Torreele, Daniela Sassella, Michael A. Bray, Lionel Hovsepian, Eric Evène, Virginie Gualano, Mathieu Felices, and Nathalie Strub-Wourgaft** *Clin Pharmacokinet.* 2014; 53(6): 565-580.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037587/>